文献速递急性肾损伤肾移植

罗沙司他(FG-4592)通过改善CD73并减少AIM2炎症小体活化保护缺血诱导的急性肾损伤

Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该研究探讨低氧诱导因子稳定剂罗沙司他(FG-4592)对肾脏缺血再灌注(IR)损伤的保护作用及机制。在AKI和肾移植后患者肾活检标本中观察到AIM2复合物蛋白表达增加及CD73信号通路活化。IR小鼠模型中,FG-4592预处理改善肌酐升高和肾小管损伤,增强CD73合成并抑制AIM2炎症小体活化,而CD73抑制剂可消除上述保护作用。

要点

  • AKI和肾移植后患者肾活检中AIM2复合物蛋白表达增加,CD73信号通路活化。
  • IR小鼠中FG-4592预处理改善肌酐升高和肾小管损伤,增强CD73并抑制AIM2炎症小体活化。
  • CD73抑制剂可消除FG-4592的肾脏保护作用及对AIM2的抑制。

核心结论

  • FG-4592对AKI的保护作用可能由诱导CD73和抑制AIM2炎症小体介导,可能为AKI治疗提供新方法。

研究设计与样本

  • 检测AKI和肾移植后患者肾活检标本中CD73与AIM2炎症小体复合物的蛋白表达水平。
  • IR小鼠模型:右肾切除后行单侧肾缺血30分钟再灌注24小时,部分小鼠腹腔注射CD73抑制剂腺苷5'-(α,β-亚甲基)二磷酸钠盐。
  • 体外用HK-2细胞研究FG-4592的功能。

主要发现

  • AKI和肾移植后患者中AIM2复合物(AIM2-凋亡相关斑点样蛋白(ASC)-活化的caspase-1)蛋白表达增加,同时检测到CD73信号通路活化。
  • FG-4592预处理改善缺血诱导的肌酐升高和肾小管损伤。
  • FG-4592给药显著增强小鼠肾脏CD73合成,但抑制AIM2炎症小体活化(降低AIM2、ASC、caspase-1、白细胞介素(IL)-1β和IL-18水平)。
  • CD73抑制剂消除了FG-4592的肾脏保护作用和对AIM2的抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypoxia-mediated inflammation plays a crucial role in renal ischaemia-reperfusion (IR)-induced acute kidney injury (AKI) and may influence renal graft survival, with no available pharmacological treatments. Here we investigate the protective effects and mechanism of roxadustat (FG-4592), a hypoxia-inducible factor stabilizer, against renal IR injury. METHODS: The protein expression levels of CD73 and AIM2 inflammasome complex were examined in kidney biopsy specimens of AKI and post-renal transplantation (PRT) patients. The effects of FG-4592 on CD73 and absent in melanoma 2 (AIM2) inflammasome components were examined in IR mice (right nephrectomy, followed by 30 min of unilateral renal ischaemia and reperfusion for 24 h), and some of the model mice received intraperitoneal administrations of adenosine 5'-(α,β-methylene)diphosphate sodium salt, which is an inhibitor of CD73. The function of FG-4592 was also investigated in vitro with HK-2 cells. RESULTS: In the AKI and PRT patients, the protein expression of AIM2 complex [AIM2-apoptosis-associated speck-like protein (ASC)-cleaved caspase-1) increased and the activation of CD73 signalling pathway was detected as well. The pretreatment of FG-4592 improved the creatinine elevation and renal tubular injuries induced by ischaemia. What's more, the administration of FG-4592 significantly enhanced CD73 synthesis in mouse kidney but suppressed the activation of the AIM2 inflammasome [decreased AIM2, ASC, caspase-1, interleukin (IL)-1β and IL-18 levels]. Notably, the renoprotection of FG-4592 and the inhibition of AIM2 were abolished by the CD73 inhibitor. CONCLUSION: FG-4592-conveyed protection against AKI might be mediated by the induction of CD73 and the suppression of the AIM2 inflammasome, which may provide a novel therapeutic method for the treatment of AKI.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yang H, Wu Y, Cheng M, et al. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation. Nephrol Dial Transplant. 2023. PMID: 36413468. doi:10.1093/ndt/gfac308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。